Navigation Links
Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 2008
Date:2/4/2008

NANJING, China, Feb. 4 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and innovative anti-cancer pharmaceuticals in the rapidly growing China market, announced today that it intends to release its 2007 fourth quarter results on Tuesday, March 4, 2008 before the market opens in the United States. Simcere's chief executive officer, Jinsheng Ren, and chief financial officer, Frank Zhigang Zhao, will host an earnings conference call to discuss the company's 2007 fourth quarter results on Tuesday, March 4, at 8 a.m. EST (Tuesday, March 4, at 9 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:

United States toll-free dial-in number: +1.800.561.2601

United States dial-in number: +1.617.614.3518

China toll-free dial-in number: 10.800.130.0399

Hong Kong dial-in number: +852.3002.1672

Please ask to be connected to Simcere's Q4 2007 Earnings Call and provide the following passcode: 77061243. Simcere also will broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's Web site at http://www.simcere.com .

Following the earnings conference call, an archive of the call will be available by dialing:

United States toll-free dial-in number: +1.888.286.8010

United States dial-in number: +1.617.801.6888

The passcode for replay participants is: 29676278. The telephone replay also will be archived on the "Investor Relations" section of the company's web site at http://www.simcere.com for seven days following the earnings announcement.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR) is a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in the rapidly growing China market. In recent years, Simcere Pharmaceutical Group has focused its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic anti- stroke medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. It currently manufactures and sells 35 pharmaceutical products including antibiotics, anti-cancer medication and anti-stroke medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Simcere Pharmaceutical Group Reports Third Quarter 2007 Results
2. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
3. Webcast Alert: Oscient Pharmaceuticals Announces Date for Release of Fourth Quarter Financial Results
4. NxStage Medical to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 7, 2008
5. Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR
6. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
7. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
8. 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation
9. Vital Training Tools Elevate New Pharmaceutical Sales Reps into Top Performers During Critical First Year
10. Tigris Pharmaceuticals Appoints Pedro Granadillo to Board of Directors
11. Tibotec Pharmaceuticals a Respectful Partner to HIV Community in Pricing of Novel New HIV NNRTI, INTELENCE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... ... System and David Konur, CEO of Cardiovascular Institute of the South announced today ... be performing a live case of an Intravascular Ultrasound Guided Coronary Atherectomy. ...
(Date:5/6/2016)... ... May 06, 2016 , ... RowdMap, ... Blue Cross BlueShield and Former Principal Deputy Administrator at Centers for Medicare and ... Company; Steve Ondra, MD, Chief Medical Officer at Health Care Service Corporation (Blue ...
(Date:5/5/2016)... ... May 05, 2016 , ... While the practice and profession of Aging ... our aging population has on communities and resources. Aging Life Care plays an important ... age-related challenges. , Aging Life Care is a holistic, client-centered approach to caring ...
(Date:5/5/2016)... ... May 05, 2016 , ... Qrono Inc. ... announced a development collaboration with the Australian critical medicine company, Phebra Pty ... schizophrenia. , LAI medicines can offer improved therapeutic benefits over oral formulations, including ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... for electronic cigarettes, requiring e-cigarette manufacturers to submit their products through an arduous ... to all vaping products that entered the market since February 15, 2007. That ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 5, 2016 ... of the  "Europe Thrombocythemia Market and ... to their offering.       ... ,The latest research Europe Thrombocythemia Market ... provides comprehensive insights into Thrombocythemia pipeline ...
(Date:5/4/2016)...  Compass Diversified Holdings (NYSE: CODI ) ... leading middle market businesses, announced today its consolidated operating ... First Quarter 2016 Highlights , Generated ... "Cash Flow") of $13.6 million for the first quarter ... million for the first quarter of 2016; , ...
(Date:5/4/2016)... 2016 According to market research "Global ... Forecast to 2022 - Industry Insights by Slice Type (High, ... Others)" by P&S Market Research, the global computed tomography ... it is expected to grow at a CAGR of 5.0% ... segment is expected to witness the faster growth, CAGR of ...
Breaking Medicine Technology: